2008 , compared to $ 12,859,000 , as of December 31 , 2007. ended June 30 , 2008 can be found on SEDAR at http : / / www.sedar.com. growth , profits , operating expenses or the company 's underlying assumptions. future results or performance may be materially different. therapeutic as well as prophylactic vaccines. that we will be able to license our TLR3 agonist. not be able to continue in our business as planned .